OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management

July 15th 2025

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Dr Qin on Ongoing Investigations of Radium-223 in mCRPC

July 15th 2025

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr Logan on Obe-Cel as a Potential Definitive Treatment in R/R B-ALL

July 15th 2025

Aaron C. Logan, MD, PhD, discusses the potential use of obe-cel as definitive treatment in adult relapsed/refractory B-ALL.

Dr Jordan on Challenges With Drug Development in Adult NF1-Associated PN

July 15th 2025

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care

July 14th 2025

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Dr Huppert on Evolving First-Line Treatment Standards for HER2+ Metastatic Breast Cancer

July 14th 2025

Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.

Dr Bekaii-Saab on the Expanding Targeted Therapy Paradigm for Biliary Tract Cancers

July 14th 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Dr Munir on a MAIC of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in CLL

July 11th 2025

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

Dr Lee on the Future Development of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

July 11th 2025

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Paulus on Accelerating Clinical Development With Real-World Data in HER2+ Breast Cancer

July 11th 2025

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Dr Kremyanskaya on the Mechanism of Action of Divesiran in Polycythemia Vera

July 11th 2025

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL

July 11th 2025

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Dr Saad on the Efficacy and Safety of Radium-223 Plus Enzalutamide in mCRPC

July 11th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL

July 11th 2025

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Dr Tan on the Clinical Relevance of T-DXd in HER2-Low/Ultralow Metastatic Breast Cancer

July 11th 2025

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC

July 11th 2025

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Dr Sinicrope on the Efficacy and Safety of mFOLFOX6 Plus Atezolizumab in Stage III dMMR CRC

July 10th 2025

Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.